A review of ustekinumab in the treatment of psoriatic arthritis

Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. The IL-23/IL-17 axis is an important pathway in the development of psoriatic disease. Ustekinumab is a fully human monoclonal IgG1 antibody that binds to the p40 subunit of IL-12 and IL-23, which, in turn, inhibits downstrea...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-04, Vol.10 (5), p.361-372
Main Authors: Roberts, Janet, O'Rielly, Darren D, Rahman, Proton
Format: Article
Language:English
Subjects:
Arthritis
clinical trials
Crohn's disease
Dermatology
IL-12/23
Immunoglobulin G
Immunotherapy
Inflammation
Inflammatory bowel disease
Interleukin 12
Interleukin 17
Interleukin 23
Monoclonal antibodies
Nonsteroidal anti-inflammatory drugs
Pathogenesis
Patients
pharmacogenetics
pharmacogenomics
pharmacokinetics
Psoriasis
Psoriatic arthritis
Quality of life
Rheumatology
Studies
Synovitis
Th-17
Tumor necrosis factor
ustekinumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriatic arthritis is an inflammatory arthritis associated with psoriasis. The IL-23/IL-17 axis is an important pathway in the development of psoriatic disease. Ustekinumab is a fully human monoclonal IgG1 antibody that binds to the p40 subunit of IL-12 and IL-23, which, in turn, inhibits downstream signaling pathways. PSUMMIT-1 and PSUMMIT-2 are two pivotal Phase III trials demonstrating global improvement in primary and secondary outcomes including inhibition of radiographic progression. Therapeutic benefit of ustekinumab for synovitis appears independent of previous disease modifying antirheumatic disease or anti-TNF exposure. At present, the data support the use of ustekinumab in the treatment of psoriatic arthritis after the failure of NSAIDs and conventional disease modifying antirheumatic diseases as an alternative to, or after failure of an anti-TNF agent.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0149